• CHECKOUT
  • English
  • German
  • US Dollar
  • Euro
  • UK Pound
  • Canadian Dollar
  • Swiss Frank
  • Australian Dollar
0 items
Cart Contents

Maxalt (rizatriptan) recommended 10 mg dosage

Adults 18 years of age and older

The recommended dose is 10 mg.

Redosing: doses should be separated by at least two hours; no more than two doses should be taken in any 24-hour period.

  • for headache recurrence within 24 hours: if headache returns after relief of the initial attack, one further dose may be taken. The above dosing limits should be observed.
  • after non-response: the effectiveness of a second dose for treatment of the same attack, when an initial dose is ineffective, has not been examined in controlled trials. Therefore, if a patient does not respond to the first dose, a second dose should not be taken for the same attack.

Clinical studies have shown that patients who do not respond to treatment of an attack are still likely to respond to treatment for subsequent attacks.

Some patients should receive the lower (5 mg) dose of Maxalt, in particular the following patient groups:

  • patients on propranolol. Administration of rizatriptan should be separated by at least two hours from administration of propranolol.
  • patients with mild or moderate renal insufficiency.
  • patients with mild to moderate hepatic insufficiency.
Children (under 12 years of age)

The use of Maxalt in patients under 12 years of age is not recommended. There are no data available on the use of rizatriptan in children under 12 years of age.

Adolescents (12-17 years of age)

The use of Maxalt Tablets in patients under 18 years of age is not recommended. In a placebo controlled study, the efficacy of Maxalt Tablets (5 mg) was not superior to placebo. The efficacy of Maxalt in patients under 18 years of age has not been established.

The use of Maxalt Melt oral lyophilisates in patients under 18 years of age is not recommended. Safety and effectiveness of Maxalt Melt oral lyophilisates in paediatric patients have not been evaluated.

Patients older than 65 years

The safety and effectiveness of rizatriptan in patients older than 65 years have not been systematically evaluated.

Products related to this article:
Maxalt
Maxalt